Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Taysha Gene Therapies, Inc.
TSHA
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$6.53
▼ -1.80%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$2.33 - $7.30
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 173.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AAV gene therapy platform optimized for CNS delivery
- Strategic partnership with UT Southwestern Medical Center providing research and clinical expertise
- Focused pipeline in underserved rare neurological diseases with limited competition
- Experienced management team with gene therapy and rare disease commercialization expertise
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Clinical trial progression and regulatory milestones for pipeline candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+52.2% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying TSHA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 13, 2026
MAY 6, 2026
Reported EPS of -$0.12 vs -$0.10 consensus (-20.0% surprise).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-20.0%
Next: May 13, 2026
Revenue trend · last 8Q
—
—
-44%
-33%
+79%
-100%
+171%
-100%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.1M
$1.8M
$2.0M
$2.3M
$2.0M
$0
$5.5M
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BMO Capital · Jun 23, 2026